Hepatitis A vaccination

Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is e...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 16; no. 7; pp. 1565 - 1573
Main Author Zhang, Li
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 02.07.2020
Taylor & Francis Group
Subjects
Hepatitis A vaccine
immunogenicity
Review
safety
vaccination strategy
safety
immunogenicity
Hepatitis A vaccine
vaccination strategy
Online AccessGet full text

Cover

Abstract Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.
AbstractList Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.
Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.
Author Zhang, Li
Author_xml – sequence: 1
  givenname: Li
  surname: Zhang
  fullname: Zhang, Li
  email: ZL9127@163.com
  organization: Shandong Center for Disease Control and Prevention
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32649265$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1PVDEUxRuDEQTWrjQs3Qz247Z9jYmREBUSEjaasGtu-_qw5E07tm8w_Pd2mGECLKSb9t6e87tNz1uyk3IKhLxn9JjRjn7iTIGUTB5zyltLKyM684rsrfozKeFqZ3tmcpcc1npD29KUg1JvyK7gCgxXco-8OwsLnOIU69HJ0S16H1Mrczogrwccazjc7Pvk1_dvP0_PZheXP85PTy5mXgqYZijEYDQzQTnaMydA82AYDb3zjPcGXeAdOg_omDbAoQkVo0I6LrQ2DsU-OV9z-4w3dlHiHMudzRjtfSOXa4tlin4M1gltfOMKZQygBpSaUs9ND9KAQGisL2vWYunmofchTQXHJ9CnNyn-ttf51mroeCd5A3zcAEr-swx1svNYfRhHTCEvq-XABVUK2GrWh8eztkMefrYJ5FrgS661hGErYdSuQrQPIdpViHYTYvN9fubzcbqPpD05ji-6v67dMQ25zPFvLmNvJ7wbcxkKJh-rFf9H_AMRO7IM
CitedBy_id crossref_primary_10_1111_jvh_14030
crossref_primary_10_1038_s41572_023_00461_2
crossref_primary_10_1590_s1678_9946202365016
crossref_primary_10_2196_53982
crossref_primary_10_7759_cureus_38388
crossref_primary_10_4081_gh_2024_1323
crossref_primary_10_1016_j_ajt_2024_12_009
crossref_primary_10_1007_s40121_024_00955_w
crossref_primary_10_3389_fpubh_2023_1326154
crossref_primary_10_3390_vaccines9111214
crossref_primary_10_1007_s12072_021_10232_4
crossref_primary_10_5501_wjv_v14_i1_97482
crossref_primary_10_3390_vaccines11071271
crossref_primary_10_1016_j_heliyon_2024_e28810
crossref_primary_10_1186_s12879_025_10458_9
crossref_primary_10_7759_cureus_68347
crossref_primary_10_3390_vaccines12060648
crossref_primary_10_1055_s_0042_1757487
crossref_primary_10_3390_children9121953
crossref_primary_10_1080_21645515_2023_2227549
crossref_primary_10_1007_s12033_023_00867_z
crossref_primary_10_1017_S0950268821001552
crossref_primary_10_1016_j_eimce_2023_03_007
crossref_primary_10_1016_j_jceh_2024_101479
crossref_primary_10_1016_j_jiac_2025_102673
crossref_primary_10_18678_dtfd_1196325
crossref_primary_10_1016_j_eimc_2023_03_003
crossref_primary_10_3389_fmed_2024_1395236
crossref_primary_10_1016_j_heliyon_2024_e36610
crossref_primary_10_7759_cureus_16635
crossref_primary_10_3390_pathogens10091081
Cites_doi 10.1093/tropej/49.6.333
10.1111/j.1365-2893.2008.01029.x
10.1126/science.182.4116.1026
10.1186/1471-2334-12-271
10.1093/infdis/159.4.621
10.1001/jama.294.2.202
10.1111/j.1708-8305.1998.tb00483.x
10.1016/j.vaccine.2018.04.015
10.4178/epih.e2019038
10.1016/S0264-410X(96)00304-0
10.1016/j.jpeds.2003.11.030
10.1016/j.vaccine.2012.10.102
10.1016/j.tmaid.2017.12.004
10.1097/00006454-200011000-00004
10.1111/tid.12217
10.1080/21645515.2015.1045167
10.1056/NEJM199208133270702
10.1093/jpids/piz045
10.1016/j.vaccine.2012.12.045
10.1111/liv.13665
10.1128/CVI.00131-10
10.1016/0166-0934(91)90056-6
10.1016/0264-410X(95)00224-O
10.4161/hv.19105
10.1016/0264-410X(92)90572-2
10.1093/infdis/jiv213
10.1111/jvh.12676
10.1016/j.vaccine.2011.08.078
10.1016/j.vaccine.2011.09.095
10.1016/0264-410X(92)90575-5
10.1016/j.vaccine.2007.11.008
10.1016/j.vaccine.2015.07.008
10.14745/ccdr.v42i09a07
10.1016/j.ijid.2017.12.021
10.1016/0264-410X(92)90557-Z
10.1002/jmv.1890200208
10.1016/j.ajog.2013.12.036
10.1016/j.tmaid.2019.101479
10.4178/epih.e2016040
10.3748/wjg.v23.i20.3589
10.1080/21645515.2017.1264798
10.1016/0264-410X(93)90151-M
10.4161/hv.28631
10.1016/j.jcv.2019.05.014
10.15585/mmwr.mm6806a6
10.1007/s00431-007-0432-0
10.3748/wjg.v6.i6.829
10.1016/S0168-8278(05)80373-3
10.1172/JCI116141
10.1371/journal.pone.0078914
10.15585/mmwr.mm6814a4
10.1108/IJHCQA-05-2019-0096
10.47102/annals-acadmedsg.V40N10p439
10.1016/S0264-410X(97)00015-7
10.1080/21645515.2016.1278329
10.1007/s12560-018-9347-3
10.1002/hep.25683
10.1016/j.ijid.2007.08.006
10.1016/S0264-410X(98)00237-0
10.1016/j.vaccine.2015.04.060
10.1016/j.vaccine.2012.10.056
10.1016/S0264-410X(03)00250-0
10.1097/MD.0000000000014364
10.1371/journal.pone.0153804
10.1016/j.jval.2015.02.004
10.1016/j.cmi.2016.06.004
10.1007/s10654-006-9081-2
10.1097/00006454-199407000-00011
10.1097/INF.0000000000001322
10.1016/j.jvacx.2019.100014
10.1007/BF01713047
10.1056/NEJMoa070546
10.1002/hep.21052
10.1097/INF.0b013e318271c4c3
10.1016/j.vaccine.2014.07.048
10.1093/infdis/171.3.676
10.1101/cshperspect.a031716
10.15585/mmwr.mm6743a5
10.1016/j.vaccine.2018.12.054
10.2188/jea.JE20130022
10.1007/s00535-006-1984-x
10.1016/S0264-410X(00)00156-0
10.5144/0256-4947.2019.37
10.1046/j.1365-2893.2000.00021.x
10.1016/S0168-8278(05)80370-8
10.1016/0166-0934(93)90147-J
10.1016/j.vaccine.2017.01.031
10.1016/j.vaccine.2012.04.038
10.1097/OLQ.0000000000000937
10.1016/j.tmaid.2014.01.005
10.1586/14760584.2016.1150182
10.1097/QAI.0b013e318183a9c0
10.1080/21645515.2018.1539600
10.2807/1560-7917.ES.2018.23.41.1800528
10.2807/1560-7917.ES.2018.23.23.1800265
ContentType Journal Article
Copyright 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020
2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
Copyright_xml – notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020
– notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
DBID 0YH
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1080/21645515.2020.1769389
DatabaseName Taylor & Francis Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate L. ZHANG
EISSN 2164-554X
EndPage 1573
ExternalDocumentID oai_doaj_org_article_b379cbc136994a74a5700c29d45943a4
PMC7482852
32649265
10_1080_21645515_2020_1769389
1769389
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
0YH
30N
4.4
53G
AALUX
ABEIZ
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AEXWM
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
DGEBU
DIK
EBS
H13
HYE
IPNFZ
KYCEM
LJTGL
M4Z
O9-
OK1
RIG
RPM
TDBHL
TFL
TFW
TTHFI
AAYXX
CITATION
NPM
7X8
5PM
GROUPED_DOAJ
ID FETCH-LOGICAL-c534t-a33f9719e6b0d1b3472e910edbc12d9abe28abc4ab1794249e661035b23779ba3
IEDL.DBID DOA
ISSN 2164-5515
2164-554X
IngestDate Wed Aug 27 01:24:07 EDT 2025
Thu Aug 21 14:32:22 EDT 2025
Fri Jul 11 09:13:48 EDT 2025
Mon Jul 21 05:56:38 EDT 2025
Tue Jul 01 02:46:12 EDT 2025
Thu Apr 24 23:02:52 EDT 2025
Wed Dec 25 09:02:34 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords safety
immunogenicity
Hepatitis A vaccine
vaccination strategy
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-a33f9719e6b0d1b3472e910edbc12d9abe28abc4ab1794249e661035b23779ba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/b379cbc136994a74a5700c29d45943a4
PMID 32649265
PQID 2423066414
PQPubID 23479
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_b379cbc136994a74a5700c29d45943a4
crossref_primary_10_1080_21645515_2020_1769389
crossref_citationtrail_10_1080_21645515_2020_1769389
pubmed_primary_32649265
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7482852
informaworld_taylorfrancis_310_1080_21645515_2020_1769389
proquest_miscellaneous_2423066414
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-07-02
PublicationDateYYYYMMDD 2020-07-02
PublicationDate_xml – month: 07
  year: 2020
  text: 2020-07-02
  day: 02
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2020
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_1_118_1
e_1_3_1_114_1
e_1_3_1_81_1
e_1_3_1_110_1
e_1_3_1_66_1
e_1_3_1_24_1
e_1_3_1_47_1
e_1_3_1_89_1
e_1_3_1_20_1
e_1_3_1_43_1
e_1_3_1_6_1
e_1_3_1_28_1
e_1_3_1_2_1
Zhang YLX (e_1_3_1_64_1) 1997; 18
Huang X (e_1_3_1_83_1) 2001; 81
e_1_3_1_93_1
e_1_3_1_106_1
e_1_3_1_70_1
e_1_3_1_102_1
e_1_3_1_55_1
e_1_3_1_36_1
e_1_3_1_78_1
e_1_3_1_13_1
e_1_3_1_51_1
e_1_3_1_97_1
e_1_3_1_32_1
e_1_3_1_74_1
e_1_3_1_17_1
e_1_3_1_59_1
e_1_3_1_119_1
e_1_3_1_61_1
e_1_3_1_80_1
e_1_3_1_115_1
e_1_3_1_111_1
e_1_3_1_23_1
hShouval D (e_1_3_1_33_1) 2019; 9
e_1_3_1_69_1
e_1_3_1_88_1
e_1_3_1_46_1
Lee HC (e_1_3_1_7_1) 2011; 40
e_1_3_1_42_1
e_1_3_1_84_1
e_1_3_1_27_1
e_1_3_1_3_1
Ki M (e_1_3_1_109_1)
Daniels D (e_1_3_1_105_1) 2009; 58
e_1_3_1_50_1
e_1_3_1_92_1
e_1_3_1_35_1
e_1_3_1_58_1
e_1_3_1_77_1
e_1_3_1_12_1
e_1_3_1_31_1
e_1_3_1_73_1
e_1_3_1_96_1
e_1_3_1_16_1
Zhuang F-C (e_1_3_1_60_1) 2010; 31
e_1_3_1_39_1
Ma JCZY (e_1_3_1_63_1) 1994; 15
Viray MA (e_1_3_1_112_1) 2018
Ministry of Health – Israel (e_1_3_1_103_1) 2015
Maritsi DN (e_1_3_1_54_1) 2017; 35
Hu X (e_1_3_1_107_1) 2019
e_1_3_1_22_1
Mauro MV (e_1_3_1_116_1) 2019; 42
e_1_3_1_8_1
e_1_3_1_41_1
e_1_3_1_87_1
Liu H-F (e_1_3_1_45_1) 2009; 23
e_1_3_1_4_1
e_1_3_1_26_1
e_1_3_1_49_1
Zhang YMJ (e_1_3_1_62_1) 1994; 13
e_1_3_1_108_1
e_1_3_1_104_1
e_1_3_1_72_1
e_1_3_1_91_1
e_1_3_1_100_1
e_1_3_1_34_1
e_1_3_1_57_1
e_1_3_1_99_1
e_1_3_1_30_1
e_1_3_1_76_1
e_1_3_1_11_1
e_1_3_1_53_1
e_1_3_1_95_1
e_1_3_1_15_1
Shouval D (e_1_3_1_21_1) 2010
e_1_3_1_38_1
e_1_3_1_19_1
Karetnyĭ IV (e_1_3_1_75_1) 1988; 33
e_1_3_1_82_1
e_1_3_1_117_1
e_1_3_1_113_1
e_1_3_1_44_1
e_1_3_1_67_1
e_1_3_1_25_1
e_1_3_1_9_1
e_1_3_1_40_1
e_1_3_1_86_1
e_1_3_1_5_1
Xu Z (e_1_3_1_85_1) 2002; 82
e_1_3_1_48_1
e_1_3_1_29_1
Advisory Committee on Immunization Practices Centers for Disease C, Prevention (e_1_3_1_68_1) 2007; 56
e_1_3_1_71_1
e_1_3_1_94_1
e_1_3_1_90_1
e_1_3_1_101_1
e_1_3_1_10_1
e_1_3_1_56_1
e_1_3_1_79_1
e_1_3_1_14_1
e_1_3_1_52_1
Wang XYMJ (e_1_3_1_65_1) 2002; 22
e_1_3_1_98_1
e_1_3_1_18_1
e_1_3_1_37_1
References_xml – start-page: 1
  volume-title: Immunization vaccines and biologicals
  year: 2010
  ident: e_1_3_1_21_1
– ident: e_1_3_1_23_1
  doi: 10.1093/tropej/49.6.333
– ident: e_1_3_1_104_1
  doi: 10.1111/j.1365-2893.2008.01029.x
– volume: 13
  start-page: 163
  issue: 6
  year: 1994
  ident: e_1_3_1_62_1
  article-title: Primary research on epidemiological effect of inactivated hepatitis A vaccine
  publication-title: Zhongguo Gonggong Weisheng Xuebao
– ident: e_1_3_1_8_1
– ident: e_1_3_1_2_1
  doi: 10.1126/science.182.4116.1026
– ident: e_1_3_1_97_1
  doi: 10.1186/1471-2334-12-271
– volume: 58
  start-page: 1
  issue: 3
  year: 2009
  ident: e_1_3_1_105_1
  article-title: Surveillance for acute viral hepatitis - United States, 2007
  publication-title: MMWR Surveill Summ
– ident: e_1_3_1_82_1
  doi: 10.1093/infdis/159.4.621
– ident: e_1_3_1_92_1
  doi: 10.1001/jama.294.2.202
– volume: 22
  start-page: 66
  issue: 2
  year: 2002
  ident: e_1_3_1_65_1
  article-title: Immunogenicity and immune persistence of live attenuated hepatitis A vaccines with different dosage
  publication-title: Zhanghua Liu Xing Bing Xue Za Zhi
– ident: e_1_3_1_19_1
  doi: 10.1111/j.1708-8305.1998.tb00483.x
– ident: e_1_3_1_70_1
  doi: 10.1016/j.vaccine.2018.04.015
– ident: e_1_3_1_9_1
– ident: e_1_3_1_108_1
  doi: 10.4178/epih.e2019038
– ident: e_1_3_1_90_1
  doi: 10.1016/S0264-410X(96)00304-0
– ident: e_1_3_1_74_1
  doi: 10.1016/j.jpeds.2003.11.030
– ident: e_1_3_1_22_1
  doi: 10.1016/j.vaccine.2012.10.102
– ident: e_1_3_1_53_1
  doi: 10.1016/j.tmaid.2017.12.004
– ident: e_1_3_1_73_1
  doi: 10.1097/00006454-200011000-00004
– ident: e_1_3_1_51_1
  doi: 10.1111/tid.12217
– ident: e_1_3_1_71_1
  doi: 10.1080/21645515.2015.1045167
– ident: e_1_3_1_36_1
  doi: 10.1056/NEJM199208133270702
– ident: e_1_3_1_99_1
  doi: 10.1093/jpids/piz045
– ident: e_1_3_1_50_1
  doi: 10.1016/j.vaccine.2012.12.045
– ident: e_1_3_1_55_1
  doi: 10.1111/liv.13665
– volume: 82
  start-page: 678
  issue: 10
  year: 2002
  ident: e_1_3_1_85_1
  article-title: [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)]
  publication-title: Zhonghua Yi Xue Za Zhi
– ident: e_1_3_1_34_1
  doi: 10.1128/CVI.00131-10
– ident: e_1_3_1_37_1
  doi: 10.1016/0166-0934(91)90056-6
– ident: e_1_3_1_27_1
  doi: 10.1016/0264-410X(95)00224-O
– volume: 35
  start-page: 711
  year: 2017
  ident: e_1_3_1_54_1
  article-title: Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study
  publication-title: Clin Exp Rheumatol
– ident: e_1_3_1_49_1
  doi: 10.4161/hv.19105
– ident: e_1_3_1_35_1
  doi: 10.1016/0264-410X(92)90572-2
– volume: 56
  start-page: 1080
  issue: 41
  year: 2007
  ident: e_1_3_1_68_1
  article-title: Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)
  publication-title: MMWR Morb Mortal Wkly Rep
– ident: e_1_3_1_43_1
  doi: 10.1093/infdis/jiv213
– ident: e_1_3_1_58_1
  doi: 10.1111/jvh.12676
– ident: e_1_3_1_40_1
  doi: 10.1016/j.vaccine.2011.08.078
– year: 2019
  ident: e_1_3_1_107_1
  article-title: Hepatitis A outbreaks in developed countries: detection, control, and prevention
  publication-title: Foodborne Pathog Dis
– ident: e_1_3_1_46_1
  doi: 10.1016/j.vaccine.2011.09.095
– volume: 81
  start-page: 465
  year: 2001
  ident: e_1_3_1_83_1
  article-title: [Horizontal transmission of live attenuated hepatitis A vaccine virus]
  publication-title: Zhonghua Yi Xue Za Zhi
– ident: e_1_3_1_84_1
  doi: 10.1016/0264-410X(92)90575-5
– ident: e_1_3_1_38_1
  doi: 10.1016/j.vaccine.2007.11.008
– ident: e_1_3_1_56_1
  doi: 10.1016/j.vaccine.2015.07.008
– ident: e_1_3_1_26_1
  doi: 10.14745/ccdr.v42i09a07
– ident: e_1_3_1_5_1
  doi: 10.1016/j.ijid.2017.12.021
– volume: 23
  start-page: 180
  year: 2009
  ident: e_1_3_1_45_1
  article-title: [The immunological effects of three doses of a live attenuated hepatitis A vaccine (H2 strain) in 8 years]
  publication-title: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
– ident: e_1_3_1_13_1
  doi: 10.1016/0264-410X(92)90557-Z
– ident: e_1_3_1_10_1
  doi: 10.1002/jmv.1890200208
– ident: e_1_3_1_80_1
– ident: e_1_3_1_81_1
  doi: 10.1016/j.ajog.2013.12.036
– volume: 31
  start-page: 1332
  year: 2010
  ident: e_1_3_1_60_1
  article-title: [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years’ follow up]
  publication-title: Zhonghua Liu Xing Bing Xue Za Zhi
– ident: e_1_3_1_47_1
  doi: 10.1016/j.tmaid.2019.101479
– ident: e_1_3_1_106_1
  doi: 10.4178/epih.e2016040
– ident: e_1_3_1_48_1
  doi: 10.3748/wjg.v23.i20.3589
– ident: e_1_3_1_89_1
  doi: 10.1080/21645515.2017.1264798
– ident: e_1_3_1_88_1
  doi: 10.1016/0264-410X(93)90151-M
– ident: e_1_3_1_42_1
  doi: 10.4161/hv.28631
– ident: e_1_3_1_115_1
  doi: 10.1016/j.jcv.2019.05.014
– ident: e_1_3_1_98_1
  doi: 10.15585/mmwr.mm6806a6
– ident: e_1_3_1_30_1
  doi: 10.1007/s00431-007-0432-0
– ident: e_1_3_1_66_1
  doi: 10.3748/wjg.v6.i6.829
– ident: e_1_3_1_14_1
  doi: 10.1016/S0168-8278(05)80373-3
– volume: 15
  start-page: 26
  issue: 3
  year: 1994
  ident: e_1_3_1_63_1
  article-title: Serological effect after vaccination of live attenuated hepatitis A vaccine
  publication-title: Hebei Yixueyuan Xuebao
– ident: e_1_3_1_16_1
  doi: 10.1172/JCI116141
– volume-title: Guidelines for vaccination
  year: 2015
  ident: e_1_3_1_103_1
– volume: 9
  issue: 2
  year: 2019
  ident: e_1_3_1_33_1
  article-title: Immunization against hepatitis A
  publication-title: Cold Spring Harb Perspect Med
– volume-title: Economic analysis of vaccination and development of guidelines for control of hepatitis A virus infection aeaadocsoh
  ident: e_1_3_1_109_1
– ident: e_1_3_1_86_1
  doi: 10.1371/journal.pone.0078914
– ident: e_1_3_1_117_1
  doi: 10.15585/mmwr.mm6814a4
– volume: 33
  start-page: 86
  year: 1988
  ident: e_1_3_1_75_1
  article-title: [Transplacental antibodies to hepatitis A virus]
  publication-title: Vopr Virusol
– ident: e_1_3_1_91_1
  doi: 10.1108/IJHCQA-05-2019-0096
– volume: 40
  start-page: 439
  year: 2011
  ident: e_1_3_1_7_1
  article-title: Changing epidemiological patterns of hepatitis A infection in Singapore
  publication-title: Ann Acad Med Singapore
  doi: 10.47102/annals-acadmedsg.V40N10p439
– ident: e_1_3_1_17_1
  doi: 10.1016/S0264-410X(97)00015-7
– ident: e_1_3_1_61_1
  doi: 10.1080/21645515.2016.1278329
– volume: 18
  start-page: 209
  issue: 4
  year: 1997
  ident: e_1_3_1_64_1
  article-title: Study on immunogenicity of live attenuated hepatitis A vaccine (H2 strain)
  publication-title: Hebei Yike Daxue Xuebao
– ident: e_1_3_1_113_1
  doi: 10.1007/s12560-018-9347-3
– ident: e_1_3_1_100_1
  doi: 10.1002/hep.25683
– ident: e_1_3_1_29_1
  doi: 10.1016/j.ijid.2007.08.006
– ident: e_1_3_1_72_1
  doi: 10.1016/S0264-410X(98)00237-0
– ident: e_1_3_1_79_1
  doi: 10.1016/j.vaccine.2015.04.060
– ident: e_1_3_1_95_1
  doi: 10.1016/j.vaccine.2012.10.056
– volume: 42
  start-page: 181
  year: 2019
  ident: e_1_3_1_116_1
  article-title: Hepatitis A outbreak affecting men who have sex with men (MSM) in South Italy
  publication-title: New Microbiol
– ident: e_1_3_1_24_1
  doi: 10.1016/S0264-410X(03)00250-0
– ident: e_1_3_1_41_1
  doi: 10.1097/MD.0000000000014364
– ident: e_1_3_1_6_1
  doi: 10.1371/journal.pone.0153804
– ident: e_1_3_1_94_1
  doi: 10.1016/j.jval.2015.02.004
– ident: e_1_3_1_44_1
  doi: 10.1016/j.cmi.2016.06.004
– ident: e_1_3_1_87_1
  doi: 10.1007/s10654-006-9081-2
– ident: e_1_3_1_77_1
  doi: 10.1097/00006454-199407000-00011
– ident: e_1_3_1_59_1
  doi: 10.1097/INF.0000000000001322
– ident: e_1_3_1_114_1
  doi: 10.1016/j.jvacx.2019.100014
– ident: e_1_3_1_15_1
  doi: 10.1007/BF01713047
– ident: e_1_3_1_69_1
  doi: 10.1056/NEJMoa070546
– ident: e_1_3_1_12_1
  doi: 10.1002/hep.21052
– ident: e_1_3_1_39_1
  doi: 10.1097/INF.0b013e318271c4c3
– ident: e_1_3_1_101_1
  doi: 10.1016/j.vaccine.2014.07.048
– ident: e_1_3_1_76_1
  doi: 10.1093/infdis/171.3.676
– ident: e_1_3_1_4_1
  doi: 10.1101/cshperspect.a031716
– ident: e_1_3_1_25_1
  doi: 10.15585/mmwr.mm6743a5
– start-page: 1
  year: 2018
  ident: e_1_3_1_112_1
  article-title: Public health investigation and response to a hepatitis A outbreak from imported scallops consumed raw-Hawaii, 2016
  publication-title: Epidemiol Infect
– ident: e_1_3_1_93_1
  doi: 10.1016/j.vaccine.2018.12.054
– ident: e_1_3_1_18_1
  doi: 10.2188/jea.JE20130022
– ident: e_1_3_1_96_1
  doi: 10.1007/s00535-006-1984-x
– ident: e_1_3_1_67_1
  doi: 10.1016/S0264-410X(00)00156-0
– ident: e_1_3_1_110_1
  doi: 10.5144/0256-4947.2019.37
– ident: e_1_3_1_3_1
  doi: 10.1046/j.1365-2893.2000.00021.x
– ident: e_1_3_1_11_1
  doi: 10.1016/S0168-8278(05)80370-8
– ident: e_1_3_1_31_1
  doi: 10.1016/0166-0934(93)90147-J
– ident: e_1_3_1_57_1
  doi: 10.1016/j.vaccine.2017.01.031
– ident: e_1_3_1_28_1
  doi: 10.1016/j.vaccine.2012.04.038
– ident: e_1_3_1_118_1
  doi: 10.1097/OLQ.0000000000000937
– ident: e_1_3_1_32_1
  doi: 10.1016/j.tmaid.2014.01.005
– ident: e_1_3_1_20_1
  doi: 10.1586/14760584.2016.1150182
– ident: e_1_3_1_102_1
– ident: e_1_3_1_52_1
  doi: 10.1097/QAI.0b013e318183a9c0
– ident: e_1_3_1_78_1
  doi: 10.1080/21645515.2018.1539600
– ident: e_1_3_1_111_1
  doi: 10.2807/1560-7917.ES.2018.23.41.1800528
– ident: e_1_3_1_119_1
  doi: 10.2807/1560-7917.ES.2018.23.23.1800265
SSID ssj0000702466
Score 2.369918
SecondaryResourceType review_article
Snippet Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1565
SubjectTerms Hepatitis A vaccine
immunogenicity
Review
safety
vaccination strategy
SummonAdditionalLinks – databaseName: Taylor & Francis Open Access
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5aEbyIz1pfVPC6uptkHzlWUYqgJwU9hUySakG20m4F_70z-yitKD143GwmJDOZnZlk9hvGzkNnPSQ-CbLIJAHGXz4ALtNAWues4_EgK-EY7h-S_pO8e46bbMJJnVZJMfSgAooov9Wk3AYmTUbcJUcXHw19jNEdxyaq5pepVbaGljikIgbhS392zII7mlc3lkQVEFnzH89fIy1YqBLI_weM6W_O6M-cyjkjdbvFNmvvsturtsM2W_H5Dluv6k1-7bJ231MCdTGcdHvdT2PtsDoL3GNPtzeP1_2growQ2FjIIjBCDFQaKZ9A6CIQMuUe7b53YCPulAHPMwNWGiB9wwjLoxkORQyc8AXBiH3Wyke5P2Bd5SKXggtt5EBmKoMQlDHY2Sig4KfDZMMNbWvYcKpe8a6jGl20YaImJuqaiR12MSP7qHAzlhFcEatnnQn2umwYjV91rUUaRKosrlEkSkmTSkPo_JYrJ2MlhZEdpuYFpYvy1GNQlSjRYskEzhqpalQxujcxuR9NJ5pcTvTMZITjtyspz6aJ3i9BLsYdli7If2Edi2_y4VsJ451KQg_kh_-Y8xHboMcyfZgfs1YxnvoTdJIKOC3V4Bs0SAJd
  priority: 102
  providerName: Taylor & Francis
Title Hepatitis A vaccination
URI https://www.tandfonline.com/doi/abs/10.1080/21645515.2020.1769389
https://www.ncbi.nlm.nih.gov/pubmed/32649265
https://www.proquest.com/docview/2423066414
https://pubmed.ncbi.nlm.nih.gov/PMC7482852
https://doaj.org/article/b379cbc136994a74a5700c29d45943a4
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4qCF7Et-tjWcFrtU3SpjmquCyCnhT0FDJJFhekilbBf-9M2l26IuzFSw_TpGRmks5MMvmGsdPUuwBFKJIys0WC8VdIgEuVSOe98zwflxGO4fauGD3Im8f8sVPqi3LCGnjgRnDnIJR24DJRaC2tkpYA2R3XXuZaChuRQNHmdYKp-A9WaHviQSXHeCBBtyCfXt8p03OiEQnDQ44kKgdIZd47hini9_9CL_3LB_2dStmxTcMNtt46lYOLhplNthSqLbbalJn83mZ7o0B50_XkY3Ax-LLOTZotwB32MLy-vxolbUGExOVC1okVYqxVpkMBqc9ASMUDmvvgUT7cawuBlxactEDLDAOrgNY3FTlwghUEK3bZSvVahX020D7zCnzqMg-y1CWkoK3FxlYDxTw9JqfSMK5FC6eiFS8ma0FFp0I0JETTCrHHzmbd3hq4jEUdLknUs8aEdh0JOAdMOwfMojnQY7qrKFPHzY5xU5nEiAUDOJlq1eDKouMSW4XXzw9DniY6ZDLD7-81Wp4NE51eQlrMe0zN6X-Oj_k31eQ5oncrSaCB_OA_GD9ka8RLTB_mR2ylfv8Mx-gk1dBny-nTCJ8ivevHtfEDrCQGPg
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VIgQX3pTlGSQ4ZklsJ44PHMqj2tJ2T63Um_FrYQXKom4WVH4Wf4U_xEycrLorUA-oB66ObU0mM56HJ98APM-8C7YMZVrlpkwx_gqpZUKmwnnvPCsmVQvHcDAuR0fi_XFxvAE_-39hqKySYuhJBIpoz2pSbkpG9yVxLxn6-GjpCwzvGA5RO79KdYWVe-H0O4Zt81e7b_Ebv2Bs593hm1HadRZIXcFFkxrOJ0rmKpQ287nlQrKAdjN463LmlbGBVcY6YSzJK0YoAc1YxgvLCJ_PGo77XoLLhSol6RbPxsu8DqoQi1ekRGVKZPY_Dv2N8hWT2HYOWMNN_ZP3u17EecYq7tyAXz0_YzHM5-GisUP3Yw1q8v9i-E243jnpyXbUqluwEerbcCW27Ty9A1ujQHXozXSebCffjHPTmFK9C0cXQtU92KxndbgPifK5l9ZnLvdWVKqymVXG4GSjLMWQAxD9N9auQ1-nJiBfdN6BtPY81sRj3fF4AMPlsq8RfuS8Ba9JgJaTCT28HZidfNTdYaQtl8rhO_JSKWGkMNTkwDHlRaEEN2IA6qz46aZNHk1ipxfNzyHgWS-rGk8qun4ydZgt5po8d3RwRY77b0XZXZKJQQQhVxYDkCtSvfIeq0_q6acWDV0KAmFkD_6B5qdwdXR4sK_3d8d7D-EaPWorstkj2GxOFuEx-p2NfdIqegIfLlrQfwODcX-V
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VIlAvvCnhuUhw3LBrex8-cCiUKKUQcaBSb8avhahoUzUbUPlX_BV-ETPr3aiJQD2gHrj6pfF47Jmxx98APEuc9Sb3eVymOo_R__KxYaKIhXXOOpZVZQvH8H6Sjw_E28PscAN-9n9hKKySfOgqAEW0ZzVt7mNX9RFxLxia-KjoM_TuGBZRNr9SdnGV-_70O3pt85d7u7jEzxkbvfn4ehx3iQVim3HRxJrzShap9LlJXGq4KJhHtemdsSlzUhvPSm2s0IbEFR0Uj1os4ZlhBM9nNMdxL8HlnD520q-RZLK81sEdxMILKVEZE5n9v6G_Ub6iEdvEAWuwqX8yftdjOM8oxdF1-NWzM8TCHA0XjRnaH2tIk_8Vv2_Atc5Ej3bCnroJG76-BVdC0s7T27A99hSF3kzn0U70TVs7DReqd-DgQqi6C5v1rPb3IJIudYVxiU2dEaUsTWKk1thYS0Me5ABEv8TKdtjrlALkq0o7iNaex4p4rDoeD2C47HYcwEfO6_CK5GfZmLDD24LZyWfVHUXK8EJanCPPpRS6EJpSHFgmncik4FoMQJ6VPtW0V0dVyPOi-DkEPO1FVeE5RY9PuvazxVyR3Y7mrUhx_O0guksy0YUg3MpsAMWKUK_MY7Wmnn5psdALQRCM7P4_0PwErn7YHal3e5P9B7BFNW04NnsIm83Jwj9Co7Mxj9ttHsGni5bz3ylifjk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatitis+A+vaccination&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Li+Zhang&rft.date=2020-07-02&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=16&rft.issue=7&rft.spage=1565&rft.epage=1573&rft_id=info:doi/10.1080%2F21645515.2020.1769389&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b379cbc136994a74a5700c29d45943a4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon